37 citations
,
March 2010 in “British Journal of Dermatology”
Oestrogen and thyrotropin-releasing hormone affect prolactin and its receptor in human skin and hair, suggesting new treatment options for related conditions.
Hmi115, a prolactinreceptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactinreceptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
ABS-201, a prolactinreceptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
The conversation is about finding the optimal concentration of topical melatonin for hair loss treatment. The user is considering making their own solution and is unsure whether a higher concentration is more effective for deactivating prolactinreceptors.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.